CA2286692A1 - Molecules presentant une pluralite de groupes fonctionnels actifs - Google Patents

Molecules presentant une pluralite de groupes fonctionnels actifs Download PDF

Info

Publication number
CA2286692A1
CA2286692A1 CA002286692A CA2286692A CA2286692A1 CA 2286692 A1 CA2286692 A1 CA 2286692A1 CA 002286692 A CA002286692 A CA 002286692A CA 2286692 A CA2286692 A CA 2286692A CA 2286692 A1 CA2286692 A1 CA 2286692A1
Authority
CA
Canada
Prior art keywords
groups
polyvalent
group
polyvalent presenter
presenter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286692A
Other languages
English (en)
Inventor
George Whitesides
James B. Tananbaum
Mathai Mammen
John Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Innoviva Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2286692A1 publication Critical patent/CA2286692A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/00756—Compositions, e.g. coatings, crystals, formulations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions polyvalentes permettant de présenter de façon polyvalente un agent thérapeutique. Ces compositions pharmaceutiques contiennent un agent de présentation polyvalent. Selon une réalisation, l'agent de présentation est formulé comme (Y)-(X-A)¿n?, Y étant un squelette, X une liaison directe ou un lien, A un groupe fonctionnel à fonction de présentation, et n un entier supérieur à 10 choisi de façon que les groupes à fonction de présentation puissent entrer en interaction avec une pluralité de sites cibles de liaison. La composition peut également comporter un vecteur pharmaceutiquement acceptable. Selon une autre réalisation, l'agent de présentation peut constituer lui-même son propre vecteur pharmaceutiquement acceptable. L'invention concerne également le traitement d'affections ou d'états. Ce traitement consiste en l'administration à un sujet d'une pluralité de groupes A de façon que le traitement se produise. Le traitement se produit du fait de l'interaction d'un agent de présentation polyvalent avec une pluralité de sites cibles de liaison B. Sous d'autres aspects, l'invention concerne, d'une part des agents de présentation polyvalents emballés avec un mode d'emploi destiné aux traitements considérés, et d'autre part des procédés de conception, d'agents de présentation polyvalent convenant particulièrement dans le cadre des procédés et traitements de l'invention. Les agents de présentation polyvalents de l'invention assurent une liaison spécifique, ce qui est relativement avantageux. En outre, ces agents de présentation polyvalents permettent des interactions positives et négatives.
CA002286692A 1997-04-11 1998-04-09 Molecules presentant une pluralite de groupes fonctionnels actifs Abandoned CA2286692A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4378197P 1997-04-11 1997-04-11
US60/043,781 1997-04-11
US4382697P 1997-04-14 1997-04-14
US60/043,826 1997-04-14
PCT/US1998/007171 WO1998046270A2 (fr) 1997-04-11 1998-04-09 Molecules presentant une pluralite de groupes fonctionnels actifs

Publications (1)

Publication Number Publication Date
CA2286692A1 true CA2286692A1 (fr) 1998-10-22

Family

ID=26720814

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286692A Abandoned CA2286692A1 (fr) 1997-04-11 1998-04-09 Molecules presentant une pluralite de groupes fonctionnels actifs

Country Status (8)

Country Link
EP (1) EP0973551A2 (fr)
JP (1) JP2002503223A (fr)
KR (1) KR20010006280A (fr)
CN (1) CN1269013A (fr)
AU (1) AU743028B2 (fr)
BR (1) BR9808521A (fr)
CA (1) CA2286692A1 (fr)
WO (1) WO1998046270A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2347027T3 (es) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University Moleculas bifuncionales y terapias basadas en las mismas.
JP3468149B2 (ja) * 1999-02-19 2003-11-17 松下電器産業株式会社 微細物体の操作装置および操作方法
ATE261754T1 (de) * 1999-05-10 2004-04-15 Glaxo Group Ltd Kristallform-screening-gerät für hohen durchsatz und dessen gebrauch
US7498025B1 (en) 1999-11-19 2009-03-03 The Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR100543171B1 (ko) * 2002-05-31 2006-01-20 한국과학기술원 분자수준에서 배향성을 조절하면서 항체 단분자막을 제조하는 방법
CA2583666A1 (fr) * 2004-10-13 2006-04-27 Ilypsa, Inc. Preparations pharmaceutiques comprenant un oligosaccharide complexant les toxines et une particule polymere
BRPI0617186A2 (pt) 2005-10-08 2011-07-19 Potentia Pharmaceuticals Inc uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
EP2139524A1 (fr) * 2007-03-23 2010-01-06 The Governors of the University of Alberta Polymères hétérobifonctionnels multivalents et leurs procédés d'utilisation
WO2009032605A2 (fr) * 2007-08-27 2009-03-12 Massachusetts Institute Of Technology Inhibiteurs du virus de la grippe couplés à un polymère bifonctionnel
DK2707384T3 (da) 2011-05-11 2022-06-07 Apellis Pharmaceuticals Inc Cellereaktiv, langtidsvirkende eller målrettede compstatinanaloger og anvendelser deraf
MX363606B (es) 2011-06-22 2019-03-28 Apellis Pharmaceuticals Inc Uso de inhibidores del complemento en trastornos crónicos.
JP2016505527A (ja) 2012-11-15 2016-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 細胞反応性、長時間作用型または標的化コンプスタチン類似体ならびに関係する組成物および方法
WO2014134297A1 (fr) * 2013-02-28 2014-09-04 The University Of Southern Mississippi Liaison covalente de bactériophages à des surfaces polymères
EP4349363A2 (fr) 2015-10-07 2024-04-10 Apellis Pharmaceuticals, Inc. Régimes posologiques
US11564995B2 (en) 2018-10-29 2023-01-31 Wisconsin Alumni Research Foundation Peptide-nanoparticle conjugates
AU2019369299A1 (en) 2018-10-29 2021-05-20 Wisconsin Alumni Research Foundation Dendritic polymers complexed with immune checkpoint inhibitors for enhanced cancer immunotherapy
JP2023500602A (ja) 2019-10-29 2023-01-10 ウィスコンシン アルムニ リサーチ ファンデイション ペプチド－ナノ粒子コンジュゲート 〔関連出願の相互参照〕 本出願は、２０１９年１０月２９日に出願されたｐｃｔ／ｕｓ２０１９／０５８４６３の一部継続出願であり、２０１９年１０月２９日に出願された米国仮出願第６２／９２７，２９３号の優先権を主張し、その全体が参照により本明細書に組み込まれる。

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463314B (sv) * 1989-03-01 1990-11-05 Biocarb Ab Sampolymerer av en n-acylerad glykosylamin och en amid, n-akryloyl-eller metakryloylglykosylaminer samt foerfarande foer framstaellning av dessa
DE19640791A1 (de) * 1996-10-02 1998-04-16 Syntesome Ges Fuer Medizinisch Glycokonjugate als Inhibitoren der viralen Zelladhäsion

Also Published As

Publication number Publication date
AU7106998A (en) 1998-11-11
KR20010006280A (ko) 2001-01-26
WO1998046270A2 (fr) 1998-10-22
AU743028B2 (en) 2002-01-17
BR9808521A (pt) 2000-05-23
WO1998046270A3 (fr) 1999-01-07
CN1269013A (zh) 2000-10-04
JP2002503223A (ja) 2002-01-29
EP0973551A2 (fr) 2000-01-26

Similar Documents

Publication Publication Date Title
AU743028B2 (en) Molecules presenting a multitude of active moieties
Percec et al. Modular synthesis of amphiphilic Janus glycodendrimers and their self-assembly into glycodendrimersomes and other complex architectures with bioactivity to biomedically relevant lectins
Roy Syntheses and some applications of chemically defined multivalent glycoconjugates
Werz et al. Carbohydrates as the next frontier in pharmaceutical research
Zanini et al. Synthesis of new α-thiosialodendrimers and their binding properties to the sialic acid specific lectin from Limax flavus
Wu et al. “Sweet” architecture-dependent uptake of glycocalyx-mimicking nanoparticles based on biodegradable aliphatic polyesters by macrophages
Roy Recent developments in the rational design of multivalent glycoconjugates
Kensinger et al. Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120
Gomez-Garcia et al. Probing carbohydrate-lectin recognition in heterogeneous environments with monodisperse cyclodextrin-based glycoclusters
Rillahan et al. On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7
Matsushita et al. Artificial Golgi apparatus: globular protein-like dendrimer facilitates fully automated enzymatic glycan synthesis
AU754331B2 (en) Treatment of bacterial infections
JPH09509979A (ja) ポリマー抱合マロン酸誘導体並びに薬剤および診断剤としてのそれらの使用
Gao et al. Exploring and controlling the polymorphism in supramolecular assemblies of carbohydrates and proteins
Hartweg et al. Synthetic glycomacromolecules of defined valency, absolute configuration, and topology distinguish between human lectins
WO1998047002A2 (fr) Bibliotheques combinatoires de presentation polyvalente et leurs utilisations
Bruehl et al. Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands
JP2010521526A (ja) 多価ヘテロ二官能性ポリマーおよびその使用方法
Eissa et al. Glycopolymer conjugates
Hoyos et al. Synthesis of glycodendrimers with antiviral and antibacterial activity
Nagao et al. Synthesis of various glycopolymers bearing sialyllactose and the effect of their molecular mobility on interaction with the influenza virus
Leyden et al. Synthesis of bivalent lactosides based on terephthalamide, N, N′-diglucosylterephthalamide, and glycophane scaffolds and assessment of their inhibitory capacity on medically relevant lectins
Neuhaus et al. Asymmetrically branched precision glycooligomers targeting langerin
Bi et al. Dynamic glycopeptide dendrimers: Synthesis and their controllable self-assembly into varied glyco-nanostructures for the biomimicry of glycans
US20040248801A1 (en) Methods and reagents for regulation of cellular responses in biological systems

Legal Events

Date Code Title Description
FZDE Dead